Delivery Order SPE2DB20D2104-SPE2DB25FMVWH
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $13,630.99 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,144.72 by the Defense Logistics Agency on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by August 5, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $63,152.32 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $30,206.63 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed price, non-set-aside contract is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $20,305.35 to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen injectors on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a single pharmaceutical procurement under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation and is being performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $26,543.31 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL units). This firm fixed-price contract, which carries no set-aside designation, is classified as a delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $33,274.72 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025, and does not include a set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMVWHDelivery Order
The Defense Logistics Agency awarded a $41,609.70 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 ml pen injectors with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle valued through December 2026 that enables the company to supply pharmaceutical products and medical supplies to military healthcare programs globally. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This contract demonstrates the company's continued role in supplying specialty medications to the military medical supply chain. Dupixent is a biologic immunosuppressant used primarily to treat moderate-to-severe atopic dermatitis and other allergic and inflammatory conditions, representing the type of specialized pharmaceutical product the company routinely delivers through its DLA contract vehicles. The compressed three-day completion window suggests this represents an urgent medical supply need within the federal military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $41.6k | 7/18/25 |